Cole Pinnow bought $332K of Cogent Biosciences (COGT)
Executed Jan 14 2025, disclosed Jan 15 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Jan 15 2025), the stock returned +2.3% (delay-adjusted); from the execution session (Jan 14 2025), +7.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Cole Pinnow (Chief Commercial Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Cogent Biosciences, Inc. (COGT). Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +2.3% from disclosure (delay-adjusted; derived). The largest single filing was $332K of COGT (43,750 sh × $7.60, as filed), executed Jan 14 2025.
Healthcare · Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→